Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 18, 2013Annals of the Rheumatic DiseasesOpen Access

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

View Full Paper
Ask AI
Bookmark
Share

Authors

WPWon ParkSamsung Medical CenterPHPaweł HrycajPoznan University of Medical SciencesSJSławomir JekaUniversity of Bydgoszcz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Park et al. (2013) studied this question.

synapsesocial.com/papers/6a704810f44fa9f079dddfd9https://doi.org/10.1136/annrheumdis-2012-203091
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The New European Medicines Agency Guideline on the Investigation of Bioequivalence2010 · 214 citations
  2. 2Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome2011 · 118 citations
  3. 3Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)2005 · 865 citations
  4. 4Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis1998 · 1,642 citations